ICAM1
Intercellular adhesion molecule 1
As of the edition of 20 October 2026, ICAM1 (intercellular adhesion molecule 1, UniProt P05362) has 3 drugs tested at it and 4 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P05362
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 14
- Disease areas
- Digestive system; Blood and lymph; Cancer; Immune system; Heart and blood vessels
- Registered trials of its drugs
- 10
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 2 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Alicaforsen | Went quiet | Phase 3 | none listed |
| BI-505 | Stopped | Phase 2 | none listed |
| VP301 | Stopped | Phase 1 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Atlantic Therapeutics | Route A |
| Akcea Therapeutics | Route A |
| Virtuoso BINco | Route A |
The other 1 company at ICAM1
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at ICAM1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.